XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue, net $ 66,056 $ 89,878 $ 232,198 $ 278,948
Less: Cost of goods sold 23,560 23,941 72,553 81,990
Less: Cost of goods sold - restructuring inventory 12,674 3,078 39,228 18,078
Gross margin 29,822 62,859 120,417 178,880
Operating expenses:        
Selling, general and administrative 45,457 58,745 155,997 236,285
Research and development 5,105 5,765 16,428 25,172
Restructuring expenses 711 3,493 10,743 13,706
Total operating expenses 51,273 68,003 183,168 275,163
Operating loss (21,451) (5,144) (62,751) (96,283)
Interest income, net 3,216 750 8,438 1,241
Other (expense) income, net (575) 511 3,092 (1,990)
Loss from operations before taxes (18,810) (3,883) (51,221) (97,032)
Provision for income taxes (501) (1,257) (2,110) (9,627)
Net loss $ (19,311) $ (5,140) $ (53,331) $ (106,659)
Loss per share:        
Basic [1] $ (0.05) $ (0.01) $ (0.13) $ (0.27)
Diluted [1] $ (0.05) $ (0.01) $ (0.13) $ (0.27)
Weighted average shares:        
Basic 408,417 404,614 407,489 399,944
Diluted 408,417 404,614 407,489 399,944
Product Revenue, Net        
Total revenue, net $ 64,903 $ 89,222 $ 214,744 $ 277,004
Licensing and Royalty Revenue        
Total revenue, net $ 1,153 $ 656 $ 17,454 $ 1,944
[1] Excluding the licensing revenue change in estimate and Medicaid change in estimate, both discussed in Note 7 – Revenue Recognition, net loss per share basic and diluted for the three and nine months ended September 30, 2023 would have been $(0.06) and $(0.19), respectively.